semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Heart Failure (CHF) eligible veterans from the Denver VAMC will have a prior primary discharge diagnosis of heart failure in the last year be at least 18 years of age, able to read and understand English have consistent access to a telephone at least one of the following: 1. Kansas City Cardiomyopathy Questionnaire (KCCQ) score less than or equal to 60; 2. a second hospitalization for with a primary discharge diagnosis of heart failure in the last year; 3. taking at least 80 mg oral furosemide (or equivalent) daily in a single or divided dose for at least 2 weeks; 4. BNP greater than or equal to 250 or NT-proBNP greater than or equal to 1000; or 5. estimated creatinine clearance 30-80 mL/min  previous diagnosis of dementia active substance abuse, defined as an AUDIT-C score greater than 7, two positive responses on substance abuse screening questions, or medical records indicating active substance abuse or dependence comorbid metastatic cancer, given the focus on heart failure palliative care nursing home resident; and diagnosis of bipolar disorder or schizophrenia
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Ischemic or non-ischemic cardiomyopathy 2. Patient meets all current for CRT (NYHA Class III-IV heart failure, QRS ≥ 120 ms, LVEF ≤ 35%, optimal medical therapy). 3. Patient willing/able to sign study informed consent and HIPAA authorization  Patient does not meet current for CRT implant 2. Mechanical aortic valve 3. Left ventricular thrombus 4. Aortic stenosis 5. No palpable femoral pulse 6. Extensive atherosclerotic disease of the aorta 7. Serum creatinine > 2.5 8. Patient not willing/able to sign study informed consent/HIPAA authorization
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Heart Failure Heart Diseases Cardiovascular Diseases Duke University Hospital inpatient adults Hospitalization for acute decompensated heart failure Dyspnea (shortness of breath) at rest or minimal exertion plus at least 1 sign of volume overload Previous heart failure hospitalization within the past 1 year At significant risk of dying from heart failure in the next 6 months Anticipated discharge from hospital with anticipated ability to return to outpatient follow-up appointments  Are not an inpatient at Duke University Hospital Acute coronary syndrome within 30 days Cardiac resynchronization therapy (CRT) within the past 3 months or current plan to implant CRT device Active myocarditis, constrictive pericarditis Severe stenotic valvular disease amenable to surgical intervention Anticipated heart transplant or ventricular assist device within 6 months Renal replacement therapy Non-cardiac terminal illness Women who are pregnant or planning to become pregnant Inability to comply with study protocol
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 15.0-45.0,  Type 1 Diabetes Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year and an insulin infusion pump for at least 6 months Age >/= 15.0 years HbA1c </= 8.0% Availability of internet access for periodic upload of study data  Diabetic ketoacidosis in the past 3 months Hypoglycemic seizure or loss of consciousness in the past 6 months History of seizure disorder (except for hypoglycemic seizure) History of any heart disease including coronary artery disease, heart failure, or arrhythmiasCoronary artery disease or heart failure Cystic fibrosis Current use of oral/inhaled glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study History of ongoing renal disease (other than microalbuminuria), or liver disease (Creatinine > 1.5 mg/dL (0.08 mmol/L)) Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as Inpatient psychiatric treatment in the past 6 months Uncontrolled adrenal disorder
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 14.0-99.0,  Transfusion Related Complications Height of usual place of residence less than 2,500 metres above sea level Perioperative hemoglobin level possibly less than 10g/dL  Emergency operation ASA classification V or VI Serious blood system diseases Dysfunction of hemoglobin Hypervolemic hemodilution Tumor metastasis Psychopathy Refuse to sign consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-80.0,  Diabetes Mellitus Heart Failure hospital admission with a diagnosis of Heart Failure (HF) with Left Ventricular Systolic Dysfunction (LVSD) or diastolic dysfunction and concomitant Diabetes (DM) type II planned discharge from hospital to home setting NYHA Class II-IV On optimal HF regimen of care including ACE-Inhibitors or ARBs beta blocking agents, and diuretics if indicated by patient fluid status ambulatory able to read and write English acceptable cognitive screening test  planned discharge to long term acute care presence of an insulin pump active foot ulcer presence of hemodynamically significant angina pectoris renal failure with hemodialysis planned cardiac surgery impaired cognition due to neurological comorbidity psychiatric diagnosis uncorrected visual or hearing problem uncorrected hearing or vision problems
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hyperlipidemia Type 2 Diabetes Diagnosis of type 2 diabetes meeting all of the following Minimum 6 month history of diabetes prior to screening visit Fasting C-peptide ≥ 0.8 ng/mL at screening visit HbA1C at screening visit 7-10% Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose regulating drugs and supplements BMI at screening visit from 25-35 kg/m2 LDL-C at screening ≥ 100 mg/dL
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Coronary Heart Disease Use of a standard-of-care statin at a stable dose, or intolerance of statins, without use of other lipid modifying therapies Fasting LDL cholesterol 90-250 mg/dL on the statin regimen above And at least one of the following Coronary heart disease (CHD) with a history of myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or prior coronary angiography demonstrating coronary atherosclerosis A CHD risk equivalent condition, including diabetes mellitus (type 1 or 2), chronic kidney disease, prior stroke, carotid disease, peripheral arterial disease, or abdominal aortic aneurism >/=2 CHD risk factors (age >/= 45 years for men or >/= 55 years for women; smoking; hypertension; low HDL cholesterol; family history of premature CHD) and a high risk of a CV event based on risk estimation systems  Severe congestive heart failure (NYHA Class III-IV) or left ventricular ejection fraction </= 35% Recent (within 3 months) MI, unstable angina, stroke, transient ischemic attack, CABG, PCI, hospital admission for heart failure, major surgery, uncontrolled cardiac arrhythmia (other than atrial fibrillation or flutter), or initiation of renal replacement therapy (dialysis) Fasting serum triglyceride level >/= 400 mg/dL Homozygous familial hypercholesterolemia Poorly controlled diabetes mellitus, hypertension or thyroid disease Liver or muscle disease, including abnormal test results at screening Pregnant or lactating The above list is not intended to contain all factors relevant to a patient's for the study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Heart Failure Dyspnea Male or female ≥ 18 years of age AHFS is the primary working diagnosis for ER management and treatment with planned admission Have received IV diuretic therapy Enrolled within 3 hours of initial diuretic dose  BNP level is ≤ 300 pg/mL (may be initially enrolled and then will be excluded for second assessment) Transplant recipients of any kind Fever > 101.5 Severe lung disease (required home O2 or daily oral steroids) Any ACS event within last 30 days Life expectancy less than 12 months for any reason Current treatment for any malignancy of any kind Cardiogenic shock and/or requiring IV inotropic therapy Pregnant or recently pregnant within last 90 days Inability to give appropriate written consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Type 1 Diabetes The subject is between 12 and 18 years of age (inclusive) The subject has had type 1 diabetes, as defined by WHO for at least 1 year or is confirmed C-peptide negative The subject will have been on insulin pump user for at least 3 months, with good knowledge of insulin self-adjustment HbA1c ≤ 12 % based on analysis from central laboratory  Non-type 1 diabetes mellitus including those secondary to chronic disease Any other physical or psychological disease likely to interfere with the normal conduct of the study and interpretation of the study results Current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers and MAO inhibitors Known or suspected allergy against insulin Subjects with clinical significant nephropathy, neuropathy or proliferative retinopathy as judged by the clinician Total daily insulin dose >= 2 IU/kg Post-menarchal girls who are pregnant or intending to become pregnant or are breastfeeding Any coexisting cardiac and respiratory condition
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Acute Coronary Syndrome Patients admitted in the coronary care unit (CCU) of the Department of Clinical and Experimental Medicine at the Federico 2nd University Hospital Patient with indication to angiographic study even if not immediately Patients referred to CCU with the diagnosis of acute myocardial infraction (AMI), type STEMI, or based on pre-admission assessment of troponin I (TpI) and myocardial band creatin kinase (CK-MB Diagnosis of performed according to standard  Patients who could not undergo angiographic study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Type 2 Diabetes BMI= 18-30 Report at least one first degree relative with family history of type 2 diabetes - Healthy with no self-report of diagnosis of chronic disease  Self-report prior diagnosis of cardiovascular disease, pulmonary disease, adult asthma, dyspnea on exertion, current bronchitis, pneumonia, or tuberculosis, vascular disease, any intercurrent infection, hematologic/oncologic, any metastatic malignancy, anemia (hematocrit <35), thrombocytopenia, neutropenia, hematologic malignancy, bleeding dyscrasias, neurologic disorder, endocrine disorder, chronic renal diseases Any illegal drug use Coumadin, heparin, beta blocker, growth hormone supplementation, or illegal drug use Skeletal-muscular injury in the last 6 months (including severe sprains, broken bones, and tendon or ligament injuries) Alcohol use in excess of 2 drinks per day Smokers
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Type 1 Diabetes Mellitus ≥21 and <65 years old 2. Clinical diagnosis of type 1 diabetes mellitus: for documented hyperglycemia (at least 1 criterion must be met) Fasting glucose ≥126 mg/dL confirmed Two-hour OGTT glucose ≥200 mg/dL confirmed HbA1c ≥6.5% documented by history confirmed Random glucose ≥200 mg/dL with symptoms No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes for requiring insulin at diagnosis (at least 1 criterion must be met) Participant required insulin at diagnosis and continually thereafter  ≥21 and <65 years old 2. Clinical diagnosis of type 1 diabetes mellitus for documented hyperglycemia (at least 1 criterion must be met) Fasting glucose ≥126 mg/dL confirmed Two-hour OGTT glucose ≥200 mg/dL confirmed HbA1c ≥6.5% documented by history confirmed Random glucose ≥200 mg/dL with symptoms No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure. HeartMate II patients who underwent surgery and follow-up at The Heart Centre of Rigshospitalet Heart failure in stable phase without the need for intravenous inotropic therapy Ischemic and non-ischemic cardiomyopathy  Severe aortic insufficiency